MTOR and cancer: Moreover, several studies have observed a synergistic antitumor effect between PI3K or mTOR inhibitors and conventional chemotherapy agents such as cisplatin in chemo-naïve or resistant cancers like melanoma, ovarian, and nasopharyngeal cancer (10–12).